FTH

AI Memo

Faeth Therapeutics

As of 2026-07-19/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-19 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

PIKTOR Phase 2 endometrial-cancer topline data • 2026-10-17

Expected move: +16%

Biggest risk

PIKTOR is the lead and highly concentrated value driver, with no reported clinical readout yet. Execution, efficacy, tolerability, enrollment, and timing risks remain material; 2025 also showed a $21.1 million net loss. [#SEC-8K-2026-03-30]

Invalidation

Break below $17 or thesis failure.

What would change my mind?

The $200 million private placement and $202.8 million of cash, cash equivalents, and marketable securities as of March 31, 2026 provide funding to advance PIKTOR through endometrial and breast-cancer milestones. [#SEC-8K-2026-05-15]

Research note

Recommendation

—

Confidence

medium

As of

2026-07-19

Base target

$30

p=50%

Bull target

$50

p=20%

Bear target

$17

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recent CFO open-market purchases
Breast-cancer Phase 1b/2 development progress
The $200 million private placement and $202.8 million of cash, cash equivalents, and marketable securities as of March 31, 2026 provide funding to advance PIKTOR through endometrial and breast-cancer milestones.

BearKey bullets

Binary clinical efficacy or tolerability disappointment in the Phase 2 endometrial-cancer program.
Clinical-trial enrollment, execution, or readout delays.
Continued operating losses and elevated R&D/G&A spending could increase financing or dilution risk.

WatchKey bullets

PIKTOR Phase 2 endometrial-cancer topline data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $30 (p=50%)

Bull/Bear spread: +93% / -34%

Vs latest close: Bull +93% · Base +16% · Bear -34%

Scenario probabilities

Bull Target: $50 (p=20%)Base Target: $30 (p=50%)Bear Target: $17 (p=30%)

Commentary

Recent news flow is moderately positive but primarily event-driven, centered on the PIKTOR program, the company/name transition, and financing. Social coverage, options data, short interest, and employee sentiment are unavailable, and analyst revisions are not present. The deterministic prior remains negative, with expected returns of -0.81% over 5 days, -2.31% over 20 days, and -3.70% over 60 days; this supports a monitoring stance rather than an aggressive bullish conclusion.

As of 2026-07-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recent CFO open-market purchases
Breast-cancer Phase 1b/2 development progress

Scenarios

Bull Target (Scenario probability)

$50 / p=20% prob

Base Target (Scenario probability)

$30 / p=50% prob

Bear Target (Scenario probability)

$17 / p=30% prob

Price $26 as of 2026-07-17

Nearest Scenario: Base (∆ 16%)

Targets vs latest close: Bull +93% · Base +16% · Bear -34%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-17
PIKTOR Phase 2 endometrial-cancer topline data
Management stated that the Phase 2 FTH-PIK-201 trial remained on track for topline data in the second half of 2026. This is the clearest near-term value inflection, but the outcome remains binary and no efficacy data are yet available. [#SEC-8K-2026-05-15]
Prob 65.00% • Move 25.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Recent CFO open-market purchases
2026-10-17
CFO Brian Stephenson reported multiple open-market purchases from June 23 through July 1, 2026. This is a modest sentiment-supporting signal, not evidence of clinical or operating success. [#SEC-FORM4-2026-07-01]
Prob 60% • Move 5% • Priced-in 25%

Long-term Catalysts

Months to a year

Breast-cancer Phase 1b/2 development progress
2027-07-19
The first patient was dosed in the FTH-PIK-101 trial for HR+/HER2- advanced breast cancer, with interim data expected in 2027. The program expands the opportunity set but remains early-stage. [#SEC-8K-2026-05-15]
Prob 55% • Move 30% • Priced-in 20%

Risks

Binary clinical efficacy or tolerability disappointment in the Phase 2 endometrial-cancer program.
Clinical-trial enrollment, execution, or readout delays.
Continued operating losses and elevated R&D/G&A spending could increase financing or dilution risk.
High concentration in the PIKTOR program and limited company coverage.
No analyst revision, consensus-surprise, or social-sentiment evidence is available in the packet.

Peers

Symbol	Summary
BBOT	Same-sector, similar-market-cap candidate identified by RankAlpha; direct program and clinical comparability are not established in the packet.
CRMD	Same-sector, similar-market-cap candidate identified by RankAlpha; insufficient evidence here for a robust operating or valuation comparison.
GYRE	Same-sector, similar-market-cap candidate identified by RankAlpha; peer fit is loose and should not drive the thesis.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-19

AI Stock Memo: FTH - Faeth Therapeutics - RankAlpha